Community-acquired Legionnaires disease: Implications for underdiagnosis and laboratory testing

Clinical Infectious Diseases

Volumn 46, Issue 9, 2008, Pages 1365-1367

  Yu, Victor L ^a,b   Stout, Janet E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Special Pathogens Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIUM CULTURE; COMMUNITY ACQUIRED PNEUMONIA; HUMAN; LABORATORY TEST; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; MORTALITY; NOTE; PRIORITY JOURNAL; SEROLOGY; STREPTOCOCCUS PNEUMONIAE;

COMMUNITY-ACQUIRED INFECTIONS; GERMANY; HUMANS; INCIDENCE; LEGIONELLA; LEGIONELLOSIS; PNEUMONIA;

EID: 42549171592     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/586742     Document Type: Note

References (24)

1. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease: risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417-22.
2. Vergis EN, Akbas E, Yu VL. Legionella as a cause of severe pneumonia. Semin Respir Crit Care Med 2000; 21:295-304.
3. Amirall J, Morata I, Riera F, et al. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J 1993; 6:14-8.
4. Bochud PY, Moser F, Erard P, et al. Community-acquired pneumonia: a prospective outpatient study. Medicine (Baltimore) 2001; 80:75-87.
5. Lagerström F, Bader M, Foldevi M, Fredlund H, Nordin-Olsson I, Holmberg H. Microbiological etiology in clinically diagnosed community-acquired pneumonia in primary care in Orebro, Sweden. Clin Microbiol Infect 2003; 9:645-52.
6. Woodhead MA, Marfarlane JT, McCracken JE, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1:671-4.
7. MacFarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community. Lancet 1993; 341:511-4.
8. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101:508-15.
9. Berntsson E, Lagerga° rd T, Strannega° rd O, Trollfors B. Etiology of community-acquired pneumonia in out-patients. Eur J Clin Microbiol 1986; 5:446-7.
10. Beovic B, Bonac B, Kese D, et al. Aetiology and clinical presentation of mild communityacquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 2003; 22:584-91.
11. Blanquer J, Blanquer R, Borrás R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991; 46:508-11.
12. Wattanathum A, Chaoprasong C, Nunthapisud P, et al. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest 2003; 123:1512-9.
13. Von Baum H, Ewig S, Marre R, et al. Community-acquired Legionella pneumonia: new insights for the German Competence Network CAPNETZ. Clin Infect Dis 2008; 46:1356-64 (in this issue).
14. Plouffe JF, File TM, Breiman RF, et al. Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Clin Infect Dis 1995; 20:1286-91.
15. Yu VL, Greenberg RN, Zadelikis N, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125:2135-9.
16. Squier CL, Stout JE, Krsytofiak S, et al. A proactive approach to prevention of health care-acquired Legionnaires' disease: the Allegheny County (Pittsburgh) experience. Am J Infect Control 2005; 33:360-7.
17. Sopena N, Sabrià M, Pedro-Botet ML, et al. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur J Clin Microbiol Infect Dis 1999; 18:852-8.
18. Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160:1294-300.
19. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
20. Mulazimoglu L, Yu VL. Can Legionnaires' disease be diagnosed by clinical criteria? A Critical Review. Chest 2001; 120:1049-53.
21. Clinical Laboratory Standards Institute (CLSI). Citizens' petition. US Food and Drug Administration docket 2007P-0273. Wayne, PA: CLSI, 2007.
22. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin Infect Dis 2006; 42:234-7.
23. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230-7.
24. Stralin K. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia. Int J Antimicrob Agents 2008; 31:3-11